Avidity Partners 13F holdings, Q3 2022
Holdings as of September 30, 2022 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 96 US equity positions worth $4.6bn in its Q3 2022 13F filing. The largest position was LLY at 7.1% of the reported book, followed by UTHR and NBIX. Against the Q2 2022 filing, it opened 14 new positions, added to 22 and reduced 14 among the top 50 holdings.
What did Avidity Partners own in Q3 2022? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2022 |
|---|---|---|---|---|---|---|---|
| 1 | LLY LILLY ELI & CO | Healthcare | 7.1% | $325.6m | 1,007,000 | 65% | added |
| 2 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 4.4% | $203.1m | 970,200 | 34% | added |
| 3 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 4.3% | $197.1m | 1,855,700 | 26% | added |
| 4 | ARVN ARVINAS INC | Healthcare | 4.2% | $193.2m | 4,343,500 | 29% | added |
| 5 | ARGX ARGENX SE | Healthcare | 3.8% | $173.6m | 491,800 | -14% | reduced |
| 6 | BIIB BIOGEN INC | Healthcare | 3.5% | $160.2m | 600,000 | 36% | added |
| 7 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 3.2% | $148.5m | 512,800 | -35% | reduced |
| 8 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.9% | $134.3m | 5,586,900 | 3% | added |
| 9 | PROTHENA CORP PLC | 2.6% | $119.3m | 1,967,000 | – | new | |
| 10 | XBI SPDR SER TR | 2.6% | $117.4m | 1,480,000 | -21% | reduced | |
| 11 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 2.4% | $108.6m | 1,389,200 | 34% | added |
| 12 | AKERO THERAPEUTICS INC | 2.3% | $106.3m | 3,122,000 | – | new | |
| 13 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 2.3% | $104.8m | 948,200 | – | new |
| 14 | HUM HUMANA INC | Healthcare | 2.2% | $102.9m | 212,000 | -49% | reduced |
| 15 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 2.1% | $98.3m | 2,538,600 | 1% | added |
| 16 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 2.1% | $97.6m | 2,079,100 | 54% | added |
| 17 | KARUNA THERAPEUTICS INC | 2.1% | $97.1m | 431,800 | 111% | added | |
| 18 | ELV ELEVANCE HEALTH INC | Healthcare | 2.1% | $94.3m | 207,600 | -53% | reduced |
| 19 | HORIZON THERAPEUTICS PUB L | 2.0% | $91.7m | 1,482,200 | -20% | reduced | |
| 20 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 2.0% | $91.5m | 4,223,100 | 18% | added |
| 21 | AVTR AVANTOR INC | Healthcare | 1.9% | $88.6m | 4,522,600 | -32% | reduced |
| 22 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.8% | $85.0m | 2,051,600 | 39% | added |
| 23 | NTRA NATERA INC | Healthcare | 1.7% | $76.0m | 1,735,000 | 27% | added |
| 24 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.5% | $68.7m | 1,538,600 | – | new |
| 25 | CATALENT INC | 1.5% | $68.0m | 940,000 | -2% | reduced | |
| 26 | INTRA-CELLULAR THERAPIES INC | 1.4% | $65.3m | 1,402,500 | 81% | added | |
| 27 | SEAGEN INC | 1.3% | $61.0m | 445,500 | -19% | reduced | |
| 28 | BIO BIO RAD LABS INC | Healthcare | 1.3% | $60.4m | 144,800 | – | new |
| 29 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 1.3% | $57.7m | 288,500 | – | new |
| 30 | APELLIS PHARMACEUTICALS INC | 1.3% | $57.6m | 844,000 | 293% | added | |
| 31 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 1.2% | $55.9m | 999,100 | -11% | reduced |
| 32 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.2% | $55.4m | 3,715,400 | 25% | added |
| 33 | KEZAR LIFE SCIENCES INC | 1.0% | $46.6m | 5,414,400 | 34% | added | |
| 34 | BELLUS HEALTH INC NEW | 1.0% | $45.9m | 4,346,700 | 2% | added | |
| 35 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.0% | $45.8m | 2,321,200 | 75% | added |
| 36 | AVIDITY BIOSCIENCES INC | 0.9% | $42.5m | 2,600,000 | 25% | added | |
| 37 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 0.9% | $42.4m | 318,300 | 413% | added |
| 38 | ZLAB ZAI LAB LTD | Healthcare | 0.9% | $42.2m | 1,234,000 | – | new |
| 39 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 0.9% | $41.5m | 1,255,374 | -13% | reduced |
| 40 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 0.9% | $41.4m | 1,981,100 | – | new |
| 41 | DXCM DEXCOM INC | Healthcare | 0.8% | $37.7m | 467,600 | – | new |
| 42 | SYK STRYKER CORPORATION | Healthcare | 0.8% | $37.4m | 184,700 | – | new |
| 43 | VERVE THERAPEUTICS INC | 0.8% | $35.8m | 1,042,706 | – | new | |
| 44 | ALT ALTIMMUNE INC | Healthcare | 0.7% | $34.3m | 2,684,000 | -10% | reduced |
| 45 | CNC CENTENE CORP DEL | Healthcare | 0.7% | $33.6m | 432,400 | – | new |
| 46 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 0.7% | $33.5m | 3,172,600 | 8% | added |
| 47 | AZN ASTRAZENECA PLC | Healthcare | 0.7% | $30.9m | 563,200 | -84% | reduced |
| 48 | NGM BIOPHARMACEUTICALS INC | 0.5% | $23.5m | 1,798,100 | – | new | |
| 49 | DECIPHERA PHARMACEUTICALS IN | 0.5% | $22.0m | 1,191,800 | -1% | reduced | |
| 50 | POINT BIOPHARMA GLOBAL INC | 0.5% | $21.8m | 2,820,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.